(ERF) Eurofins Scientific SE - Overview
Stock: Testing, Laboratory, Diagnostics, Agroscience, Environment
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.12% |
| Yield on Cost 5y | 0.80% |
| Yield CAGR 5y | -3.08% |
| Payout Consistency | 80.3% |
| Payout Ratio | 26.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 32.0% |
| Relative Tail Risk | -15.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.08 |
| Alpha | 30.37 |
| Character TTM | |
|---|---|
| Beta | 0.101 |
| Beta Downside | 0.093 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.78% |
| CAGR/Max DD | 0.22 |
Description: ERF Eurofins Scientific SE January 03, 2026
Eurofins Scientific SE (ticker ERF) is a Luxembourg-based global provider of analytical testing and laboratory services, operating through a network of more than 800 labs in over 50 countries.
The firm’s portfolio spans agroscience (e.g., seed testing, environmental safety), consumer product testing (including sustainability certifications and sensory evaluation), biopharma and clinical diagnostics, as well as food-and-feed safety (allergen, GMO, microbiology, pesticide residues, etc.). Additional capabilities cover forensic genomics, maritime and materials testing, REACH compliance, and a suite of audit, certification, and training services.
Key financial and sector drivers: • FY 2023 revenue reached €6.1 bn, with organic growth of ~12% and an EBITDA margin of ~13%, underscoring the scalability of its lab network. • Eurofins’ growth is heavily fueled by rising regulatory scrutiny on food safety, pharmaceutical quality, and ESG compliance, which is expanding demand for third-party testing and certification. • The company’s aggressive acquisition strategy-over €1 bn of deals in the past three years-has broadened its geographic reach and deepened service breadth, positioning it as a leading contract research organization (CRO) in the biotechnology sub-industry.
For a deeper dive into Eurofins’ valuation metrics and peer comparison, you might explore the detailed analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 634.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: 1.79% < 20% (prev 7.81%; Δ -6.02% < -1%) |
| CFO/TA 0.23 > 3% & CFO 2.52b > Net Income 634.5m |
| Net Debt (4.64b) to EBITDA (2.49b): 1.86 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (187.0m) vs prev -3.86% < -2% |
| Gross Margin: 18.89% > 18% (prev 0.13%; Δ 1876 % > 0.5%) |
| Asset Turnover: 114.2% > 50% (prev 91.47%; Δ 22.76% > 0%) |
| Interest Coverage Ratio: 4.24 > 6 (EBITDA TTM 2.49b / Interest Expense TTM 319.1m) |
Altman Z'' 2.26
| A: 0.02 (Total Current Assets 2.65b - Total Current Liabilities 2.43b) / Total Assets 10.98b |
| B: 0.28 (Retained Earnings 3.02b / Total Assets 10.98b) |
| C: 0.12 (EBIT TTM 1.35b / Avg Total Assets 10.89b) |
| D: 0.38 (Book Value of Equity 2.78b / Total Liabilities 7.40b) |
| Altman-Z'' Score: 2.26 = BBB |
Beneish M -3.44
| DSRI: 0.86 (Receivables 1.54b/1.42b, Revenue 12.44b/9.88b) |
| GMI: 0.69 (GM 18.89% / 13.09%) |
| AQI: 0.95 (AQ_t 0.51 / AQ_t-1 0.53) |
| SGI: 1.26 (Revenue 12.44b / 9.88b) |
| TATA: -0.17 (NI 634.5m - CFO 2.52b) / TA 10.98b) |
| Beneish M-Score: -3.44 (Cap -4..+1) = AA |
What is the price of ERF shares?
Over the past week, the price has changed by -0.21%, over one month by -1.16%, over three months by +16.00% and over the past year by +34.52%.
Is ERF a buy, sell or hold?
What are the forecasts/targets for the ERF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.3 | 0.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 74.8 | 10% |
ERF Fundamental Data Overview February 01, 2026
P/E Trailing = 30.0176
P/E Forward = 15.015
P/S = 1.6465
P/B = 2.5171
P/EG = 0.7943
Revenue TTM = 12.44b EUR
EBIT TTM = 1.35b EUR
EBITDA TTM = 2.49b EUR
Long Term Debt = 3.58b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 727.0m EUR (from shortTermDebt, last quarter)
Debt = 5.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.64b EUR (from netDebt column, last quarter)
Enterprise Value = 16.65b EUR (12.01b + Debt 5.43b - CCE 791.0m)
Interest Coverage Ratio = 4.24 (Ebit TTM 1.35b / Interest Expense TTM 319.1m)
EV/FCF = 14.00x (Enterprise Value 16.65b / FCF TTM 1.19b)
FCF Yield = 7.14% (FCF TTM 1.19b / Enterprise Value 16.65b)
FCF Margin = 9.56% (FCF TTM 1.19b / Revenue TTM 12.44b)
Net Margin = 5.10% (Net Income TTM 634.5m / Revenue TTM 12.44b)
Gross Margin = 18.89% ((Revenue TTM 12.44b - Cost of Revenue TTM 10.09b) / Revenue TTM)
Gross Margin QoQ = 10.45% (prev 22.43%)
Tobins Q-Ratio = 1.52 (Enterprise Value 16.65b / Total Assets 10.98b)
Interest Expense / Debt = 1.79% (Interest Expense 97.4m / Debt 5.43b)
Taxrate = 26.45% (81.4m / 307.8m)
NOPAT = 995.0m (EBIT 1.35b * (1 - 26.45%))
Current Ratio = 1.09 (Total Current Assets 2.65b / Total Current Liabilities 2.43b)
Debt / Equity = 1.53 (Debt 5.43b / totalStockholderEquity, last quarter 3.54b)
Debt / EBITDA = 1.86 (Net Debt 4.64b / EBITDA 2.49b)
Debt / FCF = 3.90 (Net Debt 4.64b / FCF TTM 1.19b)
Total Stockholder Equity = 4.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.83% (Net Income 634.5m / Total Assets 10.98b)
RoE = 13.53% (Net Income TTM 634.5m / Total Stockholder Equity 4.69b)
RoCE = 16.37% (EBIT 1.35b / Capital Employed (Equity 4.69b + L.T.Debt 3.58b))
RoIC = 12.08% (NOPAT 995.0m / Invested Capital 8.24b)
WACC = 4.74% (E(12.01b)/V(17.44b) * Re(6.29%) + D(5.43b)/V(17.44b) * Rd(1.79%) * (1-Tc(0.26)))
Discount Rate = 6.29% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.33%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈1.02b ; Y1≈1.26b ; Y5≈2.15b
Fair Price DCF = 328.5 (EV 62.54b - Net Debt 4.64b = Equity 57.89b / Shares 176.2m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -12.61 | EPS CAGR: -55.81% | SUE: 0.0 | # QB: 0
Revenue Correlation: 11.93 | Revenue CAGR: 3.21% | SUE: -0.01 | # QB: 0
EPS current Year (2026-12-31): EPS=4.14 | Chg30d=-0.005 | Revisions Net=-1 | Growth EPS=+6.5% | Growth Revenue=+5.9%
EPS next Year (2027-12-31): EPS=4.75 | Chg30d=+0.031 | Revisions Net=+2 | Growth EPS=+14.7% | Growth Revenue=+6.8%